Form 4: Bioventus Inc. Director Sutter Reports Stock Transactions
SEC Form 4 Filing
Director Martin P. Sutter reports the vesting and conversion of restricted stock units into Class A Common Stock of Bioventus Inc.
Summary
- On June 7, 2024, Martin P. Sutter, a director of Bioventus Inc., reported transactions involving the company's stock.
- Sutter converted 30,400 restricted stock units (RSUs) into Class A Common Stock at a price of $0 per share.
- Following the transaction, Sutter directly owns 58,748 shares of Class A Common Stock.
- Sutter also indirectly owns 13,021,324 shares through EW Healthcare Partners Acquisition Fund, L.P. and White Pine Medical, LLC.
- The RSUs vested on June 7, 2024.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company director, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of transaction: conversion of restricted stock units and vesting of RSUs. |
| 06/11/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.